Charles Dunlap - Core Laboratories Director
CLB Stock | USD 16.53 0.46 2.71% |
Director
Mr. Charles L. Dunlap has served as Independent Member of the Board of Supervisory Directors of Core Laboratories N.V. since 2013. He is Member of the Audit Committee and the Compensation Committee as well as Chairman of the Nominating, Governance and Corporationrationrate Responsibility Committee at the Company. Formerly served as Chief Executive Officer and President of TransMontaigne, and Chief Executive Officer of TransMontaigne Partners L.P., a publiclytraded master limited partnership, both based in Denver, Colorado until the end of 2014. Mr. Dunlap previously served as Chief Executive Officer and President of Pasadena Refining System, Inc., based in Houston, Texas from January 2005 to December 2008. From 2000 to 2004, Mr. Dunlap served as one of the founding partners of Strategic Advisors, L.L.C., a management consulting firm based in Baltimore, Maryland. Prior to that time, Mr. Dunlap served in various senior management and executive positions at various oil and gas companies including Crown Central Petroleum Corporation, Pacific Resources Inc., ARCO Petroleum Products Company and Clark Oil Refining Corporation since 2013.
Age | 71 |
Tenure | 11 years |
Address | 6316 Windfern Road, Houston, TX, United States, 77040 |
Phone | 713 328 2673 |
Web | https://www.corelab.com |
Core Laboratories Management Efficiency
The company has Return on Asset of 0.0605 % which means that on every $100 spent on assets, it made $0.0605 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1768 %, implying that it generated $0.1768 on every 100 dollars invested. Core Laboratories' management efficiency ratios could be used to measure how well Core Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.15. The current year's Return On Capital Employed is expected to grow to 0.21. At present, Core Laboratories' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 26 M, whereas Total Assets are forecasted to decline to about 550.2 M.Similar Executives
Showing other executives | DIRECTOR Age | ||
Barbara Duganier | MRC Global | 62 | |
Charles Still | Geospace Technologies | 73 | |
John Minge | Newpark Resources | 58 | |
Evelyn Angelle | Forum Energy Technologies | 53 | |
Gary Warren | Newpark Resources | 67 | |
Frances Hawes | Archrock | 66 | |
Jason Rebrook | Archrock | 47 | |
Carri Lockhart | Dril Quip | 49 | |
Michael McShane | Forum Energy Technologies | 66 | |
Wendell Brooks | Archrock | 68 | |
William Moody | Geospace Technologies | 76 | |
Rose Robeson | Newpark Resources | 60 | |
Leonard Anthony | MRC Global | 66 | |
Amy Schwetz | Dril Quip | 46 | |
Michael Sheen | Geospace Technologies | 76 | |
Craig Ketchum | MRC Global | 62 | |
Cornelis Linse | MRC Global | 71 | |
Darryl Willis | Dril Quip | 51 | |
Honeybourne | Archrock | 66 | |
Edgar Giesinger | Geospace Technologies | 59 | |
David Baldwin | Forum Energy Technologies | 56 |
Management Performance
Return On Equity | 0.18 | ||||
Return On Asset | 0.0605 |
Core Laboratories Leadership Team
Elected by the shareholders, the Core Laboratories' board of directors comprises two types of representatives: Core Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Core. The board's role is to monitor Core Laboratories' management team and ensure that shareholders' interests are well served. Core Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Core Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tahera Khan, Vice President Human Resources | ||
Gwendolyn Schreffler, Senior Vice President, Corporate Development and Investor Relations | ||
Lawrence Bruno, Chairman of the Supervisory Board, President, Chief Executive Officer, Chief Operating Officer | ||
Monique Eeuwijk, Non-Executive Independent Member of the Supervisory Board | ||
D Ogren, Member of the Supervisory Board | ||
Michael Flecker, Vice President Production Enhancement | ||
Christopher Hill, Chief Financial Officer, Senior Vice President | ||
Alastair Crombie, Vice President Reservoir Description | ||
Mark Elvig, Senior Vice President, Secretary, and General Counsel | ||
Harvey Klingensmith, Non-Executive Independent Member of the Supervisory Board | ||
Michael Straughen, Non-Executive Independent Member of the Supervisory Board | ||
John Ogren, Member of the Supervisory Board | ||
Charles Dunlap, Independent Member of the Board of Supervisory Directors | ||
Monty Davis, COO and Sr. VP | ||
David Hume, Vice President Reservoir Description | ||
Gwendolyn MBA, Senior Relations | ||
J Dumas, Vice President Business Development | ||
Martha Carnes, Presiding Non-Executive Lead Independent Member of the Supervisory Board | ||
Richard Bergmark, CFO, Executive VP and Supervisory Director | ||
Kevin Daniels, Vice President, Chief Accounting Officer | ||
Jacobus Schouten, Managing Director | ||
James Gresham, Senior Vice President Business Development | ||
David Demshur, Independent Chairman of the Board of Supervisory Directors and Chief Executive Officer | ||
Kwaku Temeng, Non-Executive Independent Member of the Supervisory Board | ||
Michael Kearney, Independent Supervisory Director | ||
Peter Boks, Vice President Reservoir Description | ||
Sow Teo, Treasurer VP | ||
Gregory Barnett, Non-Executive Independent Member of the Supervisory Board | ||
Chris Hill, Chief Accounting Officer and VP | ||
Margaret Kempen, Independent Member of the Board of Supervisory Directors | ||
Lucia Geuns, Independent Member of the Board of Supervisory Directors | ||
Jeffrey West, Vice President Production Enhancement | ||
Mark Tattoli, Senior Vice President General Counsel, Secretary | ||
Dumas, Vice President Business Development | ||
Gwendolyn Gresham, Senior Vice President Corporate Development and Investor Relations | ||
Jan Sodderland, Independent Member of the Board of Supervisory Directors |
Core Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Core Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.18 | ||||
Return On Asset | 0.0605 | ||||
Profit Margin | 0.07 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 1 B | ||||
Shares Outstanding | 46.66 M | ||||
Shares Owned By Insiders | 0.85 % | ||||
Shares Owned By Institutions | 99.15 % | ||||
Number Of Shares Shorted | 6.59 M | ||||
Price To Earning | 101.74 X |
Pair Trading with Core Laboratories
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Core Laboratories position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Core Laboratories will appreciate offsetting losses from the drop in the long position's value.Moving together with Core Stock
0.9 | NR | Newpark Resources Financial Report 7th of May 2024 | PairCorr |
0.74 | TS | Tenaris SA ADR Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Core Laboratories could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Core Laboratories when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Core Laboratories - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Core Laboratories NV to buy it.
The correlation of Core Laboratories is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Core Laboratories moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Core Laboratories moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Core Laboratories can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Core Laboratories NV. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Core Stock analysis
When running Core Laboratories' price analysis, check to measure Core Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Core Laboratories is operating at the current time. Most of Core Laboratories' value examination focuses on studying past and present price action to predict the probability of Core Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Core Laboratories' price. Additionally, you may evaluate how the addition of Core Laboratories to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Core Laboratories' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Core Laboratories. If investors know Core will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Core Laboratories listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.72) | Dividend Share 0.04 | Earnings Share 0.51 | Revenue Per Share 10.92 | Quarterly Revenue Growth 0.005 |
The market value of Core Laboratories is measured differently than its book value, which is the value of Core that is recorded on the company's balance sheet. Investors also form their own opinion of Core Laboratories' value that differs from its market value or its book value, called intrinsic value, which is Core Laboratories' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Core Laboratories' market value can be influenced by many factors that don't directly affect Core Laboratories' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Core Laboratories' value and its price as these two are different measures arrived at by different means. Investors typically determine if Core Laboratories is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Core Laboratories' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.